BRAF and melanoma: The efficacy and safety of D + T (dabrafenib 150 mg twice daily + trametinib 2 mg once daily) in an adjuvant setting (12-month treatment) was assessed in the phase III, randomized, double-blind, placebo-controlled trial COMBI-AD involving 870 patients with stage III melanoma with BRAF V600E or V600K mutations and pathologic involvement of regional lymph node(s).